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Sir,
It is well documented that metformin use may
cause vitamin B12 deficiency,1,2 which may lead to
hyperhomocysteinemia,3 particularly when folate
deficiency, B12 deficiency or methylenetetrahy-
drofolate reductase (MTHFR) homozygous C677T
mutation is also present, based on the metabolic
pathway of homocysteine.3 It was estimated that
5.6–7.3% of diabetic patients taking metformin
might develop evidence of B12 deficiency.1 Higher
metformin dose and longer treatment duration
as well as increased age and vegetarianism were
shown to be independent risk factors of vitamin
B12 deficiency.2 Other confounding factors in-
clude uncontrollable supplement of vitamins or
trace elements in food or any daily elements.4
The prevalence of MTHFR C677T homozygous
mutation was reported to be 5–12% in a White
population and 6–8% in Taiwanese Chinese,5 and
the homozygous mutation is related to hyper-
homocysteinemia when lower plasma folate level
coexists, but not when plasma folate level is
higher.6 Hence, it has been reported that homo-
cysteine level may3 or may not4 increase during
metformin treatment; many confounding factors
result in such conflicting data. Findings in the one
case report7 meant to call attention to the clinical
evidence that hyperhomocysteinemia caused by a
metformin-induced vitamin B12 deficiency and
a MTHFR C677T homozygous mutation may serve
as an additional independent risk factor for vas-
cular thrombosis in diabetic patients, although
many patients are on metformin therapy without
significant problems.
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